Verified Efflux Transporter Vesicles

    • Proven, high-quality ABC transporter vesicles manufactured by GenoMembrane

    • Quality assured — functionality of every batch verified by Optivia

    • Competitive pricing

    • Unmatched technical support from Optivia

    Optivia is partnering with GenoMembrane Co., Ltd. (Japan) to offer their proven, high-quality transporter vesicle products  in the US and Canada. These "inside-out" vesicles are ideal for studying efflux transporters, and can be used to complement Optivia's TransFlex™ cell-based transporter products.

    Unlike other distributors, Optivia provides further assurance of product quality by performing rigorous functional testing on each batch of products shipped from Japan. Furthermore, Optivia offers competitive pricing, unmatched technical support, and attentive customer service to ensure that you get the most out of your vesicle assays.


  • TransporterSpeciesOptivia Cat. #
    BCRP (ABCG2)HumanOPT‐VGM0008
    BSEP (ABCB11)HumanOPT‐VGM0005
    MDR1/P-gp (ABCB1)HumanOPT‐VGM0015
    MRP1 (ABCC1)HumanOPT‐VGM0010
    MRP2 (ABCC2)HumanOPT‐VGM0001
    MRP3 (ABCC3)HumanOPT‐VGM0021
    MRP4 (ABCC4)HumanOPT‐VGM0012
    MRP8 (ABCC8)HumanOPT‐VGM0013


  • Why ABC Transporter Vesicles?

    • Easily assess your compound’s interactions with efflux transporters
    • Convenient, cell-free system
    • High signal-to-noise ratios
    • Satisfy EMA guideline recommendations for secondary (non-cell-based) systems

    ATP-Binding Cassette (ABC) Transporter Vesicles allow you to easily evaluate your compound’s interactions with a given efflux transporter. Expertly produced by GenoMembrane, these inverted/inside-out vesicles are prepared from Sf9 insect cells engineered to overexpress individual efflux transporters. In cell-based systems, efflux proteins typically transport compounds out of the cells and into the environment. In an inverted vesicle format, however, the proteins are re-oriented along with the inverted membranes. As a result, they bind to the substrate in the solution surrounding the vesicles, and transport it into the vesicles where it accumulates. Quantitation of the accumulated compound allows you to determine whether your compound acts as a substrate and/or inhibitor of the transporter in question. The high levels of transporter activity and low background activity associated with these vesicles typically result in high signal-to-noise ratios, providing clear, unambiguous results. Please note, however, that highly permeant compounds may diffuse into or out of the vesicles, independent of transporter activity, minimizing differences between transporter expressing and control vesicles, potentially resulting in false negative results.

    In addition to being a convenient, cell-free system with which to evaluate your compound, vesicular systems provide a secondary system that can be used to satisfy the EMA’s recommendation for the assessment of P-gp inhibition, and possibly that of other transporters. According to EMA guidelines1, because of the high inter-laboratory variability in the estimation of P-gp inhibition, “the use of two separate systems is recommended for this transporter…. [and] could also be considered for other transporters if indicated.”



    1 Guideline on the Investigation of Drug Interactions